HHM Wealth Advisors’s NovoCure NVCR Stock Holding History

HHM Wealth Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500	Closed	-$38K	–	726
2022 Q3	$38K	Hold	500	–	–	0.01%	267
2022 Q2	$35K	Hold	500	–	–	0.01%	329
2022 Q1	$41K	Hold	500	–	–	0.01%	338
2021 Q4	$38K	Sell	500 -58	-10%	-$5.82K	0.01%	342
2021 Q3	$65K	Hold	558	–	–	0.02%	265
2021 Q2	$124K	Buy	558 +58	+12%	+$11.3K	0.03%	183
2021 Q1	$66K	Hold	500	–	–	0.02%	241
2020 Q4	$87K	Buy	+500	New	+$68.4K	0.03%	188

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HHM Wealth Advisors's NVCR Position: Q4 2022 in Review

HHM Wealth Advisors sold out of NovoCure (NVCR) in Q4 2022, closing a stake of 500 shares — an estimated $38K sold.

HHM Wealth Advisors first reported a position in NVCR in Q4 2020 and held it in 8 quarters. The position peaked at $124K in Q2 2021. 304 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

HHM Wealth Advisors reported no remaining NovoCure position as of Q4 2022 after selling out during the quarter.
HHM Wealth Advisors sold 500 NovoCure shares in Q4 2022, an estimated $38K.
HHM Wealth Advisors first reported a position in NovoCure in Q4 2020 and held it in 8 quarters.
HHM Wealth Advisors's NovoCure position peaked at $124K in Q2 2021.
304 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on HHM Wealth Advisors's 13F filing for Q4 2022, filed 19 Jan 2023.